Welcome to the e-CCO Library!

P376: Clinical effectiveness of vedolizumab in a tertiary care cohort of IBD patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Bots1*, E. van Baalen2, N. de Boer3, K. Gecse2, C. Ponsioen2, G. D'Haens2, M. Löwenberg2

Created: Thursday, 21 February 2019, 9:14 AM
P376: Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Danese1, S. Adsul*2, D. Lindner2, S. Jones3, H. Patel4, J-F. Colombel5

Created: Friday, 22 February 2019, 9:41 AM
P376: Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sands, B.E.(1)*;Jain, A.(2);Ahmad, H.A.(2);Osterman, M.(2);Memaj, A.(2);Canavan, J.B.(2);Axelrad, J.E.(3);
Created: Friday, 14 July 2023, 11:05 AM
P376: Improving stress and fatigue in a real-world setting among patients with Inflammatory Bowel Disease through a digital platform
Year: 2021
Source: ECCO'21 Virtual
Authors: Oddsson, S.(1);Gunnarsdottir, T.(1);Johannsdottir, L.(2);Amundadottir, M.(3);Frimannsdottir, A.(3);Ylanne, K.(4);Molander, P.(5);Islind, A.(2);Oskarsdottir, M.(2);Thorgeirsson, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P376: Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
Year: 2022
Source: ECCO'22
Authors: Wiken, T.(1,2);Høivik, M.L.(1,2);Buer, L.(1);Bolstad, N.(3);Moum, B.A.(1,2);Medhus, A.W.(1);
Created: Friday, 11 February 2022, 3:52 PM
P376: Therapy refractory ulcerative colitis patients may benefit from appendectomy: early result from the PASSION study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Sahami*1, C. Buskens1, D. Winter2, S. Martin2, P. Tanis1, G. van den Brink3, M. Löwenberg3, G. Cullen4, H. Mulcahy4, G. Doherty4, C. Ponsioen3, G. D’Haens3, W. Bemelman1

Created: Friday, 22 February 2019, 9:49 AM
P377 Risk factors of rectal amputation for Crohn’s disease with perianal lesion
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Yokoo, S. Yoshikawa, T. Masuda, H. Uchida, T. Nakao, H. Kashizuka, K. Yamaoka, M. Inagaki, K. Okamoto, N. Inatsugi

Created: Thursday, 30 January 2020, 10:12 AM
P377: Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wils, P.(1)*;Cartier, L.(2);Azahaf, M.(3);Hambli, S.(1);Branche, J.(1);Gérard, R.(1);Desreumaux, P.(1);Louvet, A.(1);Nachury, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P377: Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Risager Christensen*1, C. Steenholdt1, S. Buhl Næss-Schmidt1, J. Brynskov1, M. A. Ainsworth1,2

Created: Friday, 22 February 2019, 9:41 AM
P377: Complications related to varicella zoster virus infection in patients with inflammatory bowel disease in the pre-JAK inhibitors era: A prospective study
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. de Francisco1,2*, A. Castaño1, P. Flórez-Díez1, S. Martínez-González1, I. Pérez-Martínez1, N. Rodríguez-Ferreiro1, V. Jiménez-Beltrán1, A. Suárez1,2, S. Riestra1,2

Created: Thursday, 21 February 2019, 9:14 AM
P377: Evaluation of the pharmacokinetic profiles of SB5 and reference adalimumab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Shin D.1, Kang J.W.2, Park S.2, Cheong S.Y.1, Hong E.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P377: Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
Year: 2022
Source: ECCO'22
Authors: Allez, M.(1);Lewis, J.D.(2);Hanauer, S.B.(3);Danese, S.(4);Irving, P.M.(5,6);Gasink, C.(7);Hoops, T.(8);Izanec, J.L.(7);Ma, T.(7);Loftus- Jr., E.V.(9);Scherl, E.J.(10);Panaccione, R.(11);Sandborn, W.J.(12);Sands, B.E.(13);
Created: Friday, 11 February 2022, 3:52 PM
P377: Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database study
Year: 2021
Source: ECCO'21 Virtual
Authors: Bokemeyer, B.(1);Picker, N.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P377: Serum adalimumab trough levels required for mucosal healing during maintenance therapy in patients with Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. Imaeda*, Y. Morita, T. Fujimoto, K. Takahashi, M. Shioya, A. Nishida, O. Inatomi, S. Bamba, M. Sasaki, T. Tsujikawa, M. Sugimoto, A. Andoh

Created: Friday, 22 February 2019, 9:49 AM
P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.I. Calvo Moya1, I. Omella Usieto1, M.I. Vera Mendoza1, V. Matallana Royo1, I. Gonzalez Partida1, M. Manso Manrique2, B. Menchén Viso2, R. De Lucas Téllez de Meneses1, M. González Rodriguez1, P. Bella del Castillo1, Y. González Lama1

Created: Thursday, 30 January 2020, 10:12 AM
P378: Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Feagan*1, W. Sandborn2, S. Schreiber3, B. Huang4, G. Alperovich4, A. Pangan4, A. Lacerda4, G. D’Haens5

Created: Friday, 22 February 2019, 9:41 AM
P378: Immunisation practices for hepatitis B and response to vaccination in Greek patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Kalogera1*, S. Siakavellas1, E. Zambeli2, E. Tsironi3, M. Tzouvala4, D. Moschovis4, A. Kostas1, G. Axiaris2, E. Kourkoutas2, K. Filippakou3, J. Vlachogiannakos1, S. Michopoulos2, G. Papatheodoridis1, G. Bamias5

Created: Thursday, 21 February 2019, 9:14 AM
P378: Oxidative status and antioxidant capacity in children and adults with IBD: preliminary results of the OxIBDiet trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Gatti, S.(1);Cianfruglia, L.(2);Galeazzi, T.(1);Palpacelli, A.(1);Quattrini, S.(1);Quatraccioni, C.(3);Catassi, G.(1);Monachesi, C.(1);Di Sario, A.(3);Armeni, T.(2);Catassi, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P378: Pharmacokinetics of Vedolizumab and Ustekinumab in pregnant women with Inflammatory Bowel Disease and their infants exposed in-utero
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Prentice, R.(1)*;Flanagan, E.(2);Wright, E.K.(2);Gibson, P.R.(3);Rosella, S.(3);Rosella, O.(3);Goldberg, R.(1);Prideaux, L.(4);Kiburg, K.(5);Ross, A.L.(2);Burns, M.(1);Bell, S.J.(4);
Created: Friday, 14 July 2023, 11:05 AM
P378: Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open
Year: 2022
Source: ECCO'22
Authors: Allegretti, J.R.(1);Gecse, K.B.(2);Chiorean, M.V.(3);Argollo, M.(4);Guo, X.(5);Lawendy, N.(5);Su, C.(5);Mundayat, R.(6);Paulissen, J.(6);Salese, L.(5);Irving, P.M.(7);
Created: Friday, 11 February 2022, 3:52 PM